BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...
Dr. Greg Hundley: Yes, Peder, let's go. Dr. Peder Myhre: ...
Objective This study aimed to determine the proportion of capacity challenges for refusal of care, the risk factors that may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback